MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Voyager Therapeutics Inc

Ouvert

3.45 -0.58

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.38

Max

3.53

Chiffres clés

By Trading Economics

Revenu

-25M

-34M

Ventes

-18M

6.3M

P/E

Moyenne du Secteur

6.415

57.333

BPA

-0.59

Marge bénéficiaire

-549.331

Employés

172

EBITDA

-25M

-37M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+316.71% upside

Dividendes

By Dow Jones

Prochains Résultats

12 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-55M

177M

Ouverture précédente

4.03

Clôture précédente

3.45

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Voyager Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 oct. 2024, 21:31 UTC

Actualités

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

Comparaison

Variation de prix

Voyager Therapeutics Inc prévision

Objectif de Prix

By TipRanks

316.71% hausse

Prévisions sur 12 Mois

Moyen 14.71 USD  316.71%

Haut 30 USD

Bas 9 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

8

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

3.195 / 3.6Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.